Reckitt Benckiser (RKT): What the Fundamentals Show in Germ Protection

Few companies sit as close to the ordinary household routine as Reckitt Benckiser. The bottle of Dettol under the sink, the Finish tablet in the dishwasher, the packet of Nurofen in the cabinet and the tin of Enfamil on the nursery shelf all belong to the same London-listed organisation. That familiarity is what makes a Reckitt Benckiser stock analysis harder than it first appears: the group has spent the past two years deliberately shrinking itself, selling one division outright and marking another for exit, so the business today is not the business the historical accounts describe.

What Reckitt Benckiser Actually Sells

Reckitt organises itself around a set of what it calls Powerbrands, and the concentration is deliberate. The germ protection franchise, built on Dettol, Lysol and the dishwashing and laundry additive brands Finish and Vanish, is the commercial heart of the company. Alongside it sits a consumer health portfolio containing Nurofen, Gaviscon, Strepsils, Mucinex and the intimate wellness brands Durex and KY, plus vitamins and supplements sold under names such as Airborne and MegaRed.

The economics of this portfolio are worth understanding before looking at any multiple. These are low-ticket, habitual, branded purchases in categories consumers do not shop around in very carefully, which is what historically supported gross margins and advertising budgets well above those of a private-label manufacturer. It also explains the specific sensitivity of the business: when a brand loses shelf position to a supermarket own-label alternative, the effect shows up gradually in volumes rather than in a single dramatic event.

Reckitt also still owns Mead Johnson Nutrition, the infant formula business behind Enfamil and Nutramigen, acquired in 2017 for close to US$18 billion. Reckitt has classified nutrition as non-core and stated its intention to exit. Until that happens, Mead Johnson's revenue, profit and legal exposure remain inside the reported numbers, reported separately from what the group labels Core Reckitt.

The Shape of the Group Has Changed Twice

Two structural decisions dominate any current assessment of Reckitt's fundamentals, and both make year-on-year comparisons awkward.

The first is the disposal of Essential Home, the portfolio of surface care, air care and pest control brands including Air Wick, Cillit Bang, Calgon and Mortein. Reckitt agreed to sell the division to Advent International and completed the transaction on 31 December 2025. The deal valued Essential Home at an enterprise value of up to US$4.8 billion, including up to approximately US$1.3 billion of contingent and deferred consideration, and Reckitt retained a 30% equity interest in Advent's acquisition vehicle. Proceeds were substantially returned to shareholders: a special dividend of £1.6 billion was paid in February 2026, accompanied by a share consolidation.

The second is the intended exit from Mead Johnson. Reckitt has been explicit that nutrition is non-core, but as of August 2026 no completed transaction has been announced and no firm timetable has been set. For anyone conducting a Reckitt Benckiser stock analysis, that leaves an unusual situation: a substantial business sits inside the reported group while management has publicly committed to removing it. Historical group revenue, group margin and group earnings per share all therefore describe a company that is deliberately being dismantled into something smaller and, on management's argument, higher quality.

Reckitt Benckiser Fundamentals in the Latest Half Year

Reckitt reports on a half-year and full-year basis rather than in quarters. Its latest results cover the six months ended 30 June 2026, published on 29 July 2026 in sterling.

• Net revenue of £6,411 million for H1 2026, with like-for-like growth of 2.6% for Core Reckitt plus Mead Johnson combined.
• Core Reckitt like-for-like net revenue growth of 2.7%, made up of 0.5% volume growth and 2.2% price and mix. The combined figure including Mead Johnson comprised a 0.3% volume decline offset by 2.9% price and mix.
• Quarterly cadence mattered: Core Reckitt like-for-like growth reached 4.2% in the second quarter, a clear acceleration on the first.
• Adjusted operating profit for Core Reckitt plus Mead Johnson of £1,457 million, at an adjusted operating margin of 23.6%, down 100 basis points year on year.
• IFRS operating profit of £1,166 million, down 22.2%, reflecting the loss of Essential Home earnings and one-off costs.
• Adjusted diluted earnings per share of 152.1p, down 9.7% at actual exchange rates, principally reflecting the Essential Home divestment.
• Interim dividend of 88.6p per share, an increase of 5%.
• Free cash flow conversion of 42% in the half.
• Net debt at 2.5 times adjusted EBITDA, against 2.1 times a year earlier, following the £1.6 billion special dividend paid in February 2026.
• Shareholder returns of £3.0 billion in the half, with a new £500 million, twelve-month share buyback announced alongside the results.

Within the top line, germ protection was the standout, growing 10.5% in the half. That is where Dettol and Lysol sit, and it is the part of the portfolio management most wants investors to focus on.

For context, the prior full year told a stronger growth story on a larger base. In FY2025, reported on 5 March 2026, Core Reckitt like-for-like net revenue grew 5.2%, split between 1.5% volume and 3.7% price and mix, with emerging markets up 14.6%. Group adjusted operating profit was £3,543 million at a 24.9% adjusted operating margin, 40 basis points higher than the prior year, while Core Reckitt adjusted operating profit of £2,731 million rose 8.9% at constant currency at a 26.7% margin, 90 basis points higher. Roughly £2.3 billion was returned to shareholders over the year.

Reading those two periods together is the exercise. FY2025 shows what the core portfolio can do when volume and pricing both contribute; H1 2026 shows a softer start to the year, a recovering second quarter, and a margin that steps down as a profitable division leaves the group.

Management left its full-year 2026 framework unchanged at the half-year stage. Core Reckitt like-for-like net revenue growth is guided to 4% to 5% for the full year, with Mead Johnson expected to deliver low-single-digit like-for-like growth. The adjusted operating profit margin for Core Reckitt plus Mead Johnson is guided to a range of 24.9% to 25.6%, with a significantly stronger second half.

That last phrase carries most of the weight. Delivering 4% to 5% for the year after 2.7% in the first half requires the second half to run meaningfully faster, and reaching a 24.9% to 25.6% full-year margin after 23.6% requires a similar step up in profitability. The second-quarter acceleration to 4.2% is the evidence management points to; whether that cadence holds through the December year end is the most testable claim in the current guidance.

The Balance Sheet, the Dividend and the Cash Cycle

Reckitt's leverage of 2.5 times adjusted EBITDA is higher than a year earlier, and the reason is discretionary rather than operational: the group paid a £1.6 billion special dividend in February 2026 and returned £3.0 billion in total during the half. Distributing disposal proceeds mechanically raises the ratio when the divested earnings also leave the denominator. The questions from here are whether leverage trends back down and whether any Mead Johnson proceeds go to debt reduction, further buybacks, or a combination.

The 42% first-half free cash flow conversion is a figure to interpret rather than annualise. Consumer goods working capital is seasonal, and half-year conversion in this industry routinely sits well below the full-year outcome. The relevant comparison is the full-year figure against the company's own history, not the interim number in isolation.

On the dividend, the ordinary interim payment of 88.6p rose 5%, which is a straightforward signal about the board's confidence in the underlying cash generation of the retained business. The special dividend was a one-off return of disposal proceeds and should not be read as part of the recurring payout.

Risks That Deserve Named Attention

Litigation at Mead Johnson. Mead Johnson faces product liability claims alleging that cow's milk-based preterm infant formula increases the risk of necrotising enterocolitis, a serious intestinal condition affecting premature infants. More than 775 lawsuits have been consolidated in a federal multidistrict litigation in the Northern District of Illinois, with hundreds of further cases filed in state courts. Juries have previously returned substantial verdicts in this litigation, including US$60 million against Mead Johnson and US$495 million against Abbott Laboratories (ABT) in a case concerning its Similac product. A bellwether trial in the federal multidistrict litigation was scheduled for 6 July 2026. The scale of the eventual liability is genuinely unresolved, and it is directly relevant to what a buyer would pay for the nutrition business.

Execution risk on the exit. A stated intention to sell without an agreed buyer or timetable is a weak negotiating position, and the longer the process runs, the more the litigation overhang shapes the terms available.

Competitive and private-label pressure. Reckitt competes with Unilever (ULVR), Procter and Gamble (PG), Colgate-Palmolive (CL) and Haleon (HLN) across various categories, as well as with supermarket own-label products. In categories where the branded premium is modest, own-label share gains are a persistent structural pressure rather than a cyclical one.

Currency exposure. Reckitt reports in sterling but generates a large share of revenue overseas, with emerging markets a significant growth driver. Translation effects can move reported growth and earnings independently of underlying trading, which is why the company emphasises like-for-like figures.

Reading the Valuation Without Reaching a Conclusion

Reckitt's ordinary shares trade on the London Stock Exchange under RKT and, like all LSE-quoted equities of this type, are priced in pence. In August 2026 the shares were quoted around 5,244p, which is £52.44 per share, against a 52-week range of roughly 4,423p to 6,514p, giving a market capitalisation in the region of £31.7 billion. Third-party data placed the forward price-to-earnings ratio at approximately 15.7 as of 30 July 2026.

A forward price-to-earnings ratio divides the share price by an estimate of next year's earnings per share, so it is only as reliable as the estimate underneath it. In Reckitt's case that estimate carries unusual structural uncertainty, because the composition of the earnings base depends on whether and when Mead Johnson leaves the group and on what terms. Comparing that multiple with a pre-disposal history, or with a peer whose portfolio is not being reshaped, does not compare like with like. Dividend yield estimates in the same period clustered between roughly 3.4% and 4.3% depending on the data source and on whether the special dividend was counted, which is itself an illustration of how much care the current figures require.

What to Watch From Here

The useful checklist for anyone following Reckitt Benckiser fundamentals is short and specific:

• The second-half step up. Full-year results will show whether Core Reckitt reached the 4% to 5% like-for-like range and whether the margin recovered into the 24.9% to 25.6% band from 23.6% at the half.
• Volume versus price. Core volume growth of 0.5% in H1 means most of the growth came from price and mix. A shift towards volume-led growth would indicate genuine category strength rather than the recycling of past price increases.
• Germ protection momentum. The 10.5% first-half growth in the group's largest franchise sets a high comparative base for the periods ahead.
• The Mead Johnson outcome. Any announced transaction, its price, its structure and its treatment of the litigation liability would materially change the group's revenue base, margin profile and risk exposure.
• Litigation developments. Trial outcomes and any move towards settlement in the multidistrict litigation are the clearest source of discrete news.
• Leverage and capital allocation. Whether net debt to adjusted EBITDA moves back below 2.5 times, and how the £500 million buyback progresses alongside the ordinary dividend.

Reckitt today is a company mid-transformation, and its published fundamentals reflect that. The retained health and hygiene brands generate the repeat, habitual demand that supports pricing power, and the second-quarter acceleration suggests the core is responding. Set against that are a guidance range requiring a visible second-half improvement, leverage lifted by discretionary shareholder returns, and an unresolved nutrition exit carrying a live legal liability. Those are the variables to measure the next set of results against.